Dr. Zibo Li awarded three new projects
August 3, 2022
Funded by AccuNovo Biotechnologies Inc. and the NIH: STTR: Theranostic NTSR1-targeting Agents for Complementary Management of PSMA-negative Prostate Cancer The 大象传媒 team will work with Accunovo Biotech, Inc. to evaluate the newly developed agents in NTSR1 positive PC3 animal models. Specifically, 大象传媒 will perform 64Cu radiolabeling of NTSR1 targeted compounds...